FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667035> ?p ?o ?g. }

• W4385667035 endingPage "e1792906" @default.
• W4385667035 startingPage "e1792906" @default.
• W4385667035 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: BET proteins are epigenetic readers that regulate expression of critical oncoproteins involved in the pathophysiology of hematologic malignancies, including MF. INCB057643 is a small-molecule BET inhibitor evaluated as monotherapy and in combination with ruxolitinib (RUX) in pts with advanced malignancies in 2 previous phase 1/2 clinical trials. Aims: To evaluate the safety and tolerability of INCB057643 in pts with R/R MF and other advanced myeloid neoplasms. Methods: In this ongoing phase 1, 3 + 3 dose-escalation/expansion study (NCT04279847), pts aged ≥18 years received INCB057643 (4 mg once daily [qd]; escalation up to 12 mg qd) as (1) monotherapy (part 1) in R/R MF, myelodysplastic syndromes (MDS), or MDS/myeloproliferative neoplasm (MPN) overlap syndromes (MDS/MPN) or (2) added to RUX (part 2) in pts with MF and suboptimal response to RUX. The primary endpoint is safety and tolerability, including identification of dose-limiting toxicities (DLTs). Results: 13 pts have been treated in part 1 (4 mg, n=6; 8 mg, n=4; 10 mg, n=1; 12 mg, n=2), and 3 pts received 4 mg + RUX in part 2 (overall age range, 50–79 years; men, n=9; study treatment duration range, 15–314 days). 12 pts had MF, and 4 had MDS/MPN. All 6 pts in the 4-mg cohort discontinued treatment (3 for progressive disease [PD]; MF, n=2; MDS/MPN, n=1); 1 pt with MF in the 12-mg cohort discontinued for thrombocytopenia. The other 9 pts remain on treatment. Thrombocytopenia was the most common treatment-emergent adverse event (TEAE; n=9; Table) and the only TEAE leading to discontinuation (n=3). Grade ≥3 TEAEs occurring in ≥1 pt were thrombocytopenia (n=4), anemia (n=3), and hypokalemia (n=2). There were 8 serious AEs across 4 pts, with only COVID-19 occurring in >1 pt (n=2); all but one (pneumonia) were considered unrelated to study treatment. There were 2 DLTs (thrombocytopenia [MDS/MPN pt] and hyperbilirubinemia [MF pt]; both 12-mg cohort) and 2 deaths (both 4-mg cohort due to PD [MF, n=1; MDS/MPN, n=1]). Summary/Conclusion: Treatment with INCB057643 monotherapy (4 and 8 mg qd) and in combination (4 mg qd) with RUX was generally well tolerated in this pt population. The 12-mg qd monotherapy dose was not tolerated and caused 2 DLTs. There were no treatment-related fatal events. Dose finding in part 1 is ongoing with 10 mg qd, after which a recommended phase 2 dose will be declared. Combination dose escalation is also ongoing. Preliminary efficacy including spleen size and symptoms will be available for presentation. Keywords: Myelofibrosis, Myeloproliferative disorder, Myelodysplastic syndrome, Epigenetic" @default.
• W4385667035 created "2023-08-09" @default.
• W4385667035 creator A5000800861 @default.
• W4385667035 creator A5002133396 @default.
• W4385667035 creator A5006810419 @default.
• W4385667035 creator A5011862588 @default.
• W4385667035 creator A5013173470 @default.
• W4385667035 creator A5014336132 @default.
• W4385667035 creator A5020631581 @default.
• W4385667035 creator A5038004259 @default.
• W4385667035 creator A5040883292 @default.
• W4385667035 creator A5041532884 @default.
• W4385667035 creator A5046772202 @default.
• W4385667035 creator A5046784010 @default.
• W4385667035 creator A5067159029 @default.
• W4385667035 creator A5072405217 @default.
• W4385667035 creator A5086909430 @default.
• W4385667035 date "2023-08-01" @default.
• W4385667035 modified "2023-09-27" @default.
• W4385667035 title "P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY" @default.
• W4385667035 doi "https://doi.org/10.1097/01.hs9.0000971116.17929.06" @default.
• W4385667035 hasPublicationYear "2023" @default.
• W4385667035 type Work @default.
• W4385667035 citedByCount "0" @default.
• W4385667035 crossrefType "journal-article" @default.
• W4385667035 hasAuthorship W4385667035A5000800861 @default.
• W4385667035 hasAuthorship W4385667035A5002133396 @default.
• W4385667035 hasAuthorship W4385667035A5006810419 @default.
• W4385667035 hasAuthorship W4385667035A5011862588 @default.
• W4385667035 hasAuthorship W4385667035A5013173470 @default.
• W4385667035 hasAuthorship W4385667035A5014336132 @default.
• W4385667035 hasAuthorship W4385667035A5020631581 @default.
• W4385667035 hasAuthorship W4385667035A5038004259 @default.
• W4385667035 hasAuthorship W4385667035A5040883292 @default.
• W4385667035 hasAuthorship W4385667035A5041532884 @default.
• W4385667035 hasAuthorship W4385667035A5046772202 @default.
• W4385667035 hasAuthorship W4385667035A5046784010 @default.
• W4385667035 hasAuthorship W4385667035A5067159029 @default.
• W4385667035 hasAuthorship W4385667035A5072405217 @default.
• W4385667035 hasAuthorship W4385667035A5086909430 @default.
• W4385667035 hasBestOaLocation W43856670351 @default.
• W4385667035 hasConcept C126322002 @default.
• W4385667035 hasConcept C143998085 @default.
• W4385667035 hasConcept C197934379 @default.
• W4385667035 hasConcept C203092338 @default.
• W4385667035 hasConcept C2776112149 @default.
• W4385667035 hasConcept C2778375690 @default.
• W4385667035 hasConcept C2779282312 @default.
• W4385667035 hasConcept C2780007613 @default.
• W4385667035 hasConcept C2780076729 @default.
• W4385667035 hasConcept C2780817109 @default.
• W4385667035 hasConcept C2781107747 @default.
• W4385667035 hasConcept C31760486 @default.
• W4385667035 hasConcept C535046627 @default.
• W4385667035 hasConcept C71924100 @default.
• W4385667035 hasConcept C72563966 @default.
• W4385667035 hasConcept C90924648 @default.
• W4385667035 hasConceptScore W4385667035C126322002 @default.
• W4385667035 hasConceptScore W4385667035C143998085 @default.
• W4385667035 hasConceptScore W4385667035C197934379 @default.
• W4385667035 hasConceptScore W4385667035C203092338 @default.
• W4385667035 hasConceptScore W4385667035C2776112149 @default.
• W4385667035 hasConceptScore W4385667035C2778375690 @default.
• W4385667035 hasConceptScore W4385667035C2779282312 @default.
• W4385667035 hasConceptScore W4385667035C2780007613 @default.
• W4385667035 hasConceptScore W4385667035C2780076729 @default.
• W4385667035 hasConceptScore W4385667035C2780817109 @default.
• W4385667035 hasConceptScore W4385667035C2781107747 @default.
• W4385667035 hasConceptScore W4385667035C31760486 @default.
• W4385667035 hasConceptScore W4385667035C535046627 @default.
• W4385667035 hasConceptScore W4385667035C71924100 @default.
• W4385667035 hasConceptScore W4385667035C72563966 @default.
• W4385667035 hasConceptScore W4385667035C90924648 @default.
• W4385667035 hasIssue "S3" @default.
• W4385667035 hasLocation W43856670351 @default.
• W4385667035 hasLocation W43856670352 @default.
• W4385667035 hasOpenAccess W4385667035 @default.
• W4385667035 hasPrimaryLocation W43856670351 @default.
• W4385667035 hasRelatedWork W2573662340 @default.
• W4385667035 hasRelatedWork W2891695269 @default.
• W4385667035 hasRelatedWork W2970332576 @default.
• W4385667035 hasRelatedWork W3092224889 @default.
• W4385667035 hasRelatedWork W3096152999 @default.
• W4385667035 hasRelatedWork W3206923461 @default.
• W4385667035 hasRelatedWork W3215791468 @default.
• W4385667035 hasRelatedWork W4376133764 @default.
• W4385667035 hasRelatedWork W4379281294 @default.
• W4385667035 hasRelatedWork W4385702350 @default.
• W4385667035 hasVolume "7" @default.
• W4385667035 isParatext "false" @default.
• W4385667035 isRetracted "false" @default.
• W4385667035 workType "article" @default.